Literature DB >> 29645207

25 years of quinacrine sterilization experience in Chile: review of 2,592 cases.

J Zipper1, V Trujillo2.   

Abstract

OBJECTIVES: To assess short-term side effects, long-term risks and efficacy of quinacrine sterilization (QS) in Chile.
METHODS: Review experience of 2,592 cases sterilized with 2 or 3 transcervical insertions of 252 mg quinacrine as pellets since 1977; review the Chilean pre-clinical experience and epidemiological studies on cervical, endometrial and other cancers.
RESULTS: Among 2,592 women who underwent QS, the total number of pregnancies was 119 (4.6%); 59 (49.5%) were carried to term with no birth defects related to QS. Nine cases were ectopic pregnancies. The ectopic pregnancy risk per 1,000 woman-years was 0.41, similar to that for surgical sterilization. The cumulative life-table pregnancy rates per 100 women at 10 years varied from 5.2 to 6.9. Mild and transient side effects were reported in 13.5% of quinacrine intrauterine insertions and pelvic inflammatory disease was diagnosed in 4 cases (0.15%). Long-term follow-up of quinacrine-sterilized patients shows no increased risk of cervical, endometrial or other cancer.
CONCLUSIONS: QS efficacy at 10 years is comparable to widely accepted tubal clip and single point bipolar electrocoagulation laparoscopic procedures. QS has a low risk of serious, immediate side effects. No long-term risks have been identified after 25 years of use.
© 2003 International Federation of Gynecology and Obstetrics.

Entities:  

Keywords:  non-surgical female sterilization; quinacrine sterilization

Year:  2003        PMID: 29645207     DOI: 10.1016/S0020-7292(03)90086-5

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  1 in total

1.  Quinacrine inhibits GSTA1 activity and induces apoptosis through G1/S arrest and generation of ROS in human non-small cell lung cancer cell lines.

Authors:  Makhan Kumar; Ansie Martin; Snehal Nirgude; Bibha Chaudhary; Sukanta Mondal; Angshuman Sarkar
Journal:  Oncotarget       Date:  2020-05-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.